Compugen vs Viridian Therapeutics, Inc.\de
Compugen and Viridian Therapeutics, Inc.\de are similar in size: $72.8m and $70.8m of revenue in their latest fiscal years. Viridian Therapeutics, Inc.\de grew faster (23359.9% against 161.1%). Compugen kept more of each dollar of sales as profit: a net margin of 48.6% against -483.6%. Compugen carries less debt relative to equity (0.0% against 6.9%).
| Latest fiscal year | CompugenCGEN, 2025 | Viridian Therapeutics, Inc.\deVRDN, 2025 |
|---|---|---|
| Revenue | $72.8m | $70.8m |
| Revenue growth | 161.1% | 23359.9% |
| Net income | $35.3m | −$343m |
| Operating margin | 43.1% | -512.9% |
| Net margin | 48.6% | -483.6% |
| Return on equity | 44.8% | -49.2% |
| Free cash flow | $31.3m | −$277m |
| Cash | $90.6m | $212m |
| Total debt | $0 | $49.9m |
| Debt to equity | 0.0% | 6.9% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 252 |
| Market value | $191m | $2.85bn |
| Price vs our value range | Below our value range | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 0 buys, 12 sales | 1 buys, 3 sales |